Efflux Limits Tumor Drug Delivery Despite Disrupted BBB
- 1 June 2021
- journal article
- editorial
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 42 (6) , 426-428
Abstract
No abstract availableKeywords
Funding Information
- NIH
This publication has 9 references indexed in Scilit:
- ATP-binding cassette transporters restrict drug delivery and efficacy against brain tumors even when blood-brain barrier integrity is lostCell Reports Medicine, 2021
- Expression of P-gp in Glioblastoma: What we can Learn from Brain DevelopmentCurrent Pharmaceutical Design, 2020
- Enhancing Brain Retention of a KIF11 Inhibitor Significantly Improves its Efficacy in a Mouse Model of GlioblastomaScientific Reports, 2020
- Physical blood-brain barrier disruption induced by focused ultrasound does not overcome the transporter-mediated efflux of erlotinibJournal of Controlled Release, 2018
- Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of GlioblastomaThe Journal of Pharmacology and Experimental Therapeutics, 2017
- Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical dataNeuro-Oncology, 2017
- Impact of Blood–Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain MetastasesClinical Cancer Research, 2016
- Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brainExpert Reviews in Molecular Medicine, 2011
- Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast CancerClinical Cancer Research, 2010